EVICEL 90 MG
FIBRINOGEN (HUMAN) : 90 MG THROMBIN (HUMAN) : 1200 UNIT · DIN 02348497 · OMRIX BIOPHARMACEUTICALS LTD
Health Canada status: CANCELLED POST MARKET
What is EVICEL?
EVICEL 90 MG contains FIBRINOGEN (HUMAN) : 90 MG THROMBIN (HUMAN) : 1200 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02348497, held by OMRIX BIOPHARMACEUTICALS LTD, supplied as SOLUTION ; KIT for TOPICAL administration. Health Canada currently lists it as cancelled post market, status dated 06-Jun-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02348497 |
|---|---|
| Brand name | EVICEL |
| Generic / active ingredient | FIBRINOGEN (HUMAN) : 90 MG THROMBIN (HUMAN) : 1200 UNIT |
| Manufacturer | OMRIX BIOPHARMACEUTICALS LTD |
| Strength | 90 MG |
| Dosage form | SOLUTION ; KIT |
| Route of administration | TOPICAL |
| Schedule | Schedule D |
| ATC code | B02BC30 COMBINATIONS |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 06-Jun-2023 |
| Original market date | 2011-03-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B02BC30 COMBINATIONS. 5 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARTISS | 3000 KIU | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02326167 |
| TISSEEL | 125 MG | KIT | BAXTER CORPORATION | MARKETED | DIN 02326132 |
| TISSEEL | 125 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02326175 |
| VISTASEAL | 400 MG / 5 ML | SOLUTION | INSTITUTO GRIFOLS S.A. | MARKETED | DIN 02514257 |
| VISTASEAL | 80 MG / 1 ML | SOLUTION | INSTITUTO GRIFOLS S.A. | MARKETED | DIN 02514222 |
| QUIXIL | 60.0 MG | KIT ; SOLUTION | OMRIX BIOPHARMACEUTICALS LTD | APPROVED | DIN 02283980 |
| TACHOSIL | 2 UNIT | PATCH | CORZA MEDICAL GMBH | APPROVED | DIN 02439026 |
| TACHOSIL | 2 UNIT | PATCH | CORZA MEDICAL GMBH | APPROVED | DIN 02439034 |
| TACHOSIL | 5.5 MG | PATCH | CORZA MEDICAL GMBH | DORMANT | DIN 02439042 |
| TISSEEL KIT VH 0.5 | 55 MG | KIT ; POWDER FOR SOLUTION ; LIQUID | BAXTER AG | CANCELLED POST MARKET | DIN 02233272 |
Who else supplies COMBINATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.